cdc2-like kinases/Dyrk1A inhibitors (NCATS)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namecdc2-like kinases/Dyrk1A inhibitors (NCATS)
Drug Alias Namecdc2-like kinases/dual-specificity tyrosine-regulated kinase 1A inhibitors (NCATS)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitorsClk dual-specificity kinase inhibitors
TargetsDual specificity protein kinase CLKDual-specificity tyrosine-phosphorylation regulated kinase 1A
Therapy Area/IndicationsDown SyndromeAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Center For Advancing Translational Sciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Center For Advancing Translational SciencesNational Human Genome Research Institute
Active IndicationsN/A
Inactive IndicationsDown SyndromeAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A